CD4+ and CD8+ responses declined to similar levels in both groups after three months, and remained detectable at low levels with medians ranging between 0.2–0.5 IU/mL (IQR 0.2–0.7) for uninfected and 0.7–1.4 IU/mL (IQR 0.1–4.5) for the post-COVID-19 group. The gene discussed is CD4; the disease is COVID-19.